Neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA–IIIB non-small cell lung cancer: integrated multidimensional biomarker analysis from a phase II study
Guoxin Cai, Pingping Song, Zhendan Wang, Jiarui Zhao, Kaiyue Wang, Min Li, Xingpeng Wang, Jingyu Zhu, Jing Xu, Baiyang Huang, Xiao Han, Haiyan Zhou, Chao Xie, Shuai Fu, Hui Jia, Feifei Teng, Suzhen Wang, Hongfu Sun, Wanhu Li, Jinming Yu, Xue Meng · 2026
Read Neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA–IIIB non-small cell lung cancer: integrated multidimensional biomarker analysis from a phase II study by Guoxin Cai, Pingping Song, Zhendan Wang, Jiarui Zhao, Kaiyue Wang, Min Li, Xingpeng Wang, Jingyu Zhu, Jing Xu, Baiyang Huang, Xiao Han, Haiyan Zhou, Chao Xie, Shuai Fu, Hui Jia, Feifei Teng, Suzhen Wang, Hongfu Sun, Wanhu Li, Jinming Yu, Xue Meng (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13289363.txt.
Description
Guoxin Cai and colleagues report a 2026 phase II biomarker study on camrelizumab plus chemotherapy before surgery for lung cancer. Patients had resectable stage IIIA to IIIB non-small cell lung cancer, a group where relapse risk stays high. Three cycles of the immune drug plus chemotherapy came first, then surgery to remove the tumor.
Thirty patients enrolled, and 27 reached radical surgery after treatment. Complete clearing of tumor in removed tissue occurred in a third of patients, while major shrinkage occurred in half as reported. After a median follow-up of 27.2 months, about three quarters stayed disease-free at two years in the data. Severe treatment side effects were uncommon. Higher starting levels of certain CD8 T cells in blood and tumor linked to full clearing.
Catalog record
| CREATOR | Guoxin Cai, Pingping Song, Zhendan Wang, Jiarui Zhao, Kaiyue Wang, Min Li, Xingpeng Wang, Jingyu Zhu, Jing Xu, Baiyang Huang, Xiao Han, Haiyan Zhou, Chao Xie, Shuai Fu, Hui Jia, Feifei Teng, Suzhen Wang, Hongfu Sun, Wanhu Li, Jinming Yu, Xue Meng |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50439 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |